KP415

Unassigned

New Medicines

Attention-deficit hyperactivity disorder (ADHD)

Information

New molecular entity
Not Known
KemPharm

Development and Regulatory status

None
None
Phase III Clinical Trials

Category

Prodrug of d-threo-methylphenidate (d-MPH) in an extended release formulation (KP 415)
Prevalence of ADHD is estimated to be around 2.4% of children in the UK [1].
Attention-deficit hyperactivity disorder (ADHD)
Oral